Table 1.
Demographic information and assay results for cohorts after primary vaccination.
| Disease Categories | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HCW (n = 18) | NISP (n = 28) | ISP (n = 427) | Active Heme Malignancy (n = 29) | Inactive Heme Malignancy (n = 65) | Primary anemia (n = 9) | Solid Malignancy (n = 24) | Solid Organ Transplant (n = 67) | Autoimmune Disease (n = 149) | 1° Immuno-deficiency (n = 42) | Multiple Categories (n = 42) | |
| On ISMT,% (n) | 0 (0) | 0 (0) | 69 (295) | 59 (17) | 45 (29) | 11 (1) | 46 (11) | 100 (67) | 89 (133) | 2 (1) | 86 (36) |
| Male:female ratio | 0.5:1 | 1.5:1 | 0.8:1 | 1.9:1 | 1.3:1 | 0.5:1 | 0.8:1 | 1.5:1 | 0.5:1 | 1.0:1 | 0.6:1 |
| Age, median (IQR), years | 43.5 (38.2–47.8) | 44.0 (35.8–64.2) | 49.0 (24.0–64.0) | 56.0 (29.0–70.0) | 39.0 (19.0–65.0) | 19.0 (16.0–24.0) | 20.5 (15.5–63.2) | 41.0 (17.0–59.5) | 53.0 (38.0–63.0) | 47.0 (32.8–65.5) | 57.5 (35.0–71.0) |
| IgG days since vaccine*, median (IQR) | 20.0 (17.0–21.0) | 158.0 (62.5–194.5) | 80.0 (41.0–127.0) | 48.0 (32.0–97.0) | 48.0 (32.8–95.8) | 78.0 (41.0–102.0) | 99.0 (53.2–129.5) | 66.0 (39.5–105.0) | 108.5 (62.8–152.2) | 81.0 (41.0–118.0) | 81.0 (45.5–122.5) |
| Anti-S1 IgG, median (IQR), OD ratio | 9.6 (9.3–9.9) | 5.7 (3.6–8.2) | 2.8 (0.2–7.1) | 0.7 (0.1–3.9) | 5.1 (0.3–8.4) | 8.5 (6.8–8.9) | 7.2 (4.9–8.7) | 3.3 (0.3–7.7) | 1.2 (0.2–5.2) | 3.5 (1.8–7.0) | 1.6 (0.2–6.1) |
| Anti-S1 IgG,% positive (n) | 100 (18/18) | 100 (27/27) | 62.3 (261/419) | 50 (14/28) | 69 (44/64) | 89 (8/9) | 88 (21/24) | 66 (44/67) | 53 (76/144) | 78 (32/41) | 52 (22/42) |
| ACE2 Blocking%, median (IQR) | 68.0 (50.0–90.8) | 12.0 (0.0–85.0) | 0.0 (0.0–43.8) | 0.0 (0.0–4.0) | 14.5 (0.0–94.8) | 100.0 (33.0–100.0) | 28.0 (0.0–85.5) | 0.5 (0.0–62.2) | 0.0 (0.0–10.2) | 0.0 (0.0–43.0) | 0.0 (0.0–22.0) |
| ACE2 Blocking,% positive (n) | 94 (17/18) | 44 (12/27) | 32.0 (134/419) | 18 (5/28) | 47 (30/64) | 78 (7/9) | 54 (13/24) | 34 (23/67) | 22 (31/144) | 34 (14/41) | 26 (11/42) |
| IGRA days since vaccine†, median (IQR) | 20.0 (17.0–21.0) | 185.0 (148.8–203.5) | 98.0 (56.0–142.0) | 86.5 (47.0–131.5) | 70.0 (41.8–121.2) | 78.0 (41.0–102.0) | 99.0 (60.2–137.2) | 81.0 (58.0–119.5) | 115.0 (78.0–156.0) | 83.5 (49.0–119.2) | 99.5 (64.0–147.5) |
| IFN-γ Response median (IQR), IU/mL | 1.3 (1.1–5.6) | 2.3 (1.4–4.3) | 1.9 (0.2–5.2) | 0.5 (0.1–4.4) | 2.8 (0.7–6.4) | 3.3 (3.0–8.3) | 4.6 (1.1–9.4) | 0.8 (0.1–2.3) | 2.2 (0.5–5.7) | 3.2 (0.4–7.0) | 0.4 (0.1–3.1) |
| IFN-γ Response,% positive (n) | 100 (18/18) | 92 (24/26) | 71.2 (277/389) | 58 (15/26) | 80 (45/56) | 100 (9/9) | 82 (18/22) | 58 (34/59) | 77 (106/137) | 75 (30/40) | 50 (20/40) |
Note: not all patients had both anti-S1 IgG and IGRA results available.
*Number of days elapsed between primary vaccination and anti-S1 IgG testing.
†Number of days elapsed between primary vaccination and IGRA testing.